DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergen… Read more
DMK Pharmaceuticals Corporation (DMKPQ) - Total Liabilities
Latest total liabilities as of September 2023: $14.25 Million USD
Based on the latest financial reports, DMK Pharmaceuticals Corporation (DMKPQ) has total liabilities worth $14.25 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DMK Pharmaceuticals Corporation - Total Liabilities Trend (2016–2022)
This chart illustrates how DMK Pharmaceuticals Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DMK Pharmaceuticals Corporation Competitors by Total Liabilities
The table below lists competitors of DMK Pharmaceuticals Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
European Green Transition PLC
LSE:EGT
|
UK | GBX187.89K |
|
Pacific Horizon Investment Trust
LSE:PHI
|
UK | GBX43.04 Million |
|
Rua Life Sciences PLC
LSE:RUA
|
UK | GBX1.93 Million |
|
Ces Synergies Inc
PINK:CESX
|
USA | $8.87 Million |
|
Caerus Mineral Resources PLC
LSE:CMRS
|
UK | GBX1.59 Million |
|
UCM RESITA S.A.
RO:UCM
|
Romania | RON529.73 Million |
Liability Composition Analysis (2016–2022)
This chart breaks down DMK Pharmaceuticals Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DMK Pharmaceuticals Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DMK Pharmaceuticals Corporation (2016–2022)
The table below shows the annual total liabilities of DMK Pharmaceuticals Corporation from 2016 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-09-30 | $11.58 Million | -6.71% |
| 2021-09-30 | $12.42 Million | -54.64% |
| 2020-09-30 | $27.37 Million | +84.44% |
| 2019-09-30 | $14.84 Million | +27.20% |
| 2018-09-30 | $11.67 Million | -1.60% |
| 2017-09-30 | $11.86 Million | -5.20% |
| 2016-09-30 | $12.51 Million | -- |